Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. J of Skin. 2022;6(6):s70. doi:10.25251/skin.6.supp.70